WO2010093191A3 - Nouveaux composés efficaces en tant qu'inhibiteurs de xanthine oxydase, leur procédé de préparation et composition pharmaceutique les contenant - Google Patents

Nouveaux composés efficaces en tant qu'inhibiteurs de xanthine oxydase, leur procédé de préparation et composition pharmaceutique les contenant Download PDF

Info

Publication number
WO2010093191A3
WO2010093191A3 PCT/KR2010/000893 KR2010000893W WO2010093191A3 WO 2010093191 A3 WO2010093191 A3 WO 2010093191A3 KR 2010000893 W KR2010000893 W KR 2010000893W WO 2010093191 A3 WO2010093191 A3 WO 2010093191A3
Authority
WO
WIPO (PCT)
Prior art keywords
same
preparing
pharmaceutical composition
novel compounds
xanthine oxidase
Prior art date
Application number
PCT/KR2010/000893
Other languages
English (en)
Other versions
WO2010093191A2 (fr
Inventor
Sung Pil Choi
Geun Tae Kim
Jeong Uk Song
Tae Hun Kim
Dong Chul Lim
Seung Wan Kang
Hyung Jin Kim
Original Assignee
Lg Life Sciences Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lg Life Sciences Ltd. filed Critical Lg Life Sciences Ltd.
Publication of WO2010093191A2 publication Critical patent/WO2010093191A2/fr
Publication of WO2010093191A3 publication Critical patent/WO2010093191A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La présente invention concerne de nouveaux composés qui sont efficaces en tant qu'inhibiteur de la xanthine oxydase, leur procédé de préparation et une composition pharmaceutique comportant une quantité efficace desdits composés.
PCT/KR2010/000893 2009-02-13 2010-02-12 Nouveaux composés efficaces en tant qu'inhibiteurs de xanthine oxydase, leur procédé de préparation et composition pharmaceutique les contenant WO2010093191A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20090011963 2009-02-13
KR10-2009-0011963 2009-02-13

Publications (2)

Publication Number Publication Date
WO2010093191A2 WO2010093191A2 (fr) 2010-08-19
WO2010093191A3 true WO2010093191A3 (fr) 2010-12-09

Family

ID=42562195

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2010/000893 WO2010093191A2 (fr) 2009-02-13 2010-02-12 Nouveaux composés efficaces en tant qu'inhibiteurs de xanthine oxydase, leur procédé de préparation et composition pharmaceutique les contenant

Country Status (2)

Country Link
KR (1) KR20100092909A (fr)
WO (1) WO2010093191A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9156845B2 (en) 2012-06-29 2015-10-13 Pfizer Inc. 4-(substituted amino)-7H-pyrrolo[2,3-d] pyrimidines as LRRK2 inhibitors

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011036130A1 (fr) * 2009-09-24 2011-03-31 F. Hoffmann-La Roche Ag Dérivés d'indole utilisés comme modulateurs de crac
CN103328434A (zh) 2011-01-28 2013-09-25 纳幕尔杜邦公司 制备2-氨基苯甲酰胺衍生物的方法
EP2545964A1 (fr) 2011-07-13 2013-01-16 Phenex Pharmaceuticals AG Nouveaux composés se liant au fxr (nr1 h4) et modulant son activité
SI2958913T1 (sl) 2013-02-20 2018-12-31 Lg Chem, Ltd. Sfingozin-1-fosfat receptor agonisti, postopki za njegovo pripravo in farmacevtski sestavki, ki ga vsebujejo kot aktivno sredstvo
CA2859099C (fr) 2013-08-13 2022-01-11 Natreon, Inc. Extraits de terminalia chebula et de terminalia bellerica pour inhibition de xanthine-oxydase
US9695171B2 (en) 2013-12-17 2017-07-04 Pfizer Inc. 3,4-disubstituted-1 H-pyrrolo[2,3-b]pyridines and 4,5-disubstituted-7H-pyrrolo[2,3-c]pyridazines as LRRK2 inhibitors
JP6086105B2 (ja) 2014-09-24 2017-03-01 信越半導体株式会社 Ｓｏｉウェーハの製造方法
CN106478619B (zh) * 2015-08-29 2019-09-24 江苏新元素医药科技有限公司 一类黄嘌呤氧化酶抑制剂及其应用
CN106478500B (zh) 2015-09-02 2020-02-11 广东东阳光药业有限公司 羧酸取代的（杂）芳环类衍生物及其制备方法和用途
EP3350178B1 (fr) 2015-09-14 2021-10-20 Pfizer Inc. Nouveaux dérivés imidazo [4,5-c]quinoline et imidazo [4,5-c][1,5]naphthyridine utilisés comme inhibiteurs de lrrk2
ES2921432T3 (es) 2016-06-13 2022-08-25 Gilead Sciences Inc Derivados de azetidina como moduladores de FXR (NR1H4)
CA2968836A1 (fr) 2016-06-13 2017-12-13 Gilead Sciences, Inc. Composes modulant fxr (nr1h4)
CN110612286A (zh) * 2017-02-28 2019-12-24 广东东阳光药业有限公司 氰基取代的稠合双环衍生物及其制备方法和用途
KR20220119520A (ko) 2017-03-28 2022-08-29 길리애드 사이언시즈, 인코포레이티드 간 질환을 치료하기 위한 치료 조합물
PT3911647T (pt) 2019-01-15 2024-03-04 Gilead Sciences Inc Composto de isoxazole como agonista de fxr e composições farmacêuticas que o contenham
JP2022519906A (ja) 2019-02-19 2022-03-25 ギリアード サイエンシーズ， インコーポレイテッド Ｆｘｒアゴニストの固体形態
CN114080386B (zh) * 2019-06-19 2024-05-31 株式会社Lg化学 制备吲哚或吲唑化合物的方法
EP3971183A4 (fr) * 2019-06-19 2022-08-10 LG Chem, Ltd. Procédé de production d'un composé d'indole ou d'indazole
CN111072634B (zh) * 2020-01-03 2022-07-22 中国医科大学 1-取代-3-取代-5-取代酰胺-1h-吲哚类化合物及其制备方法和应用
CA3218011A1 (fr) * 2021-04-29 2022-11-10 Jiangsu Atom Bioscience And Pharmaceutical Co., Ltd. Un inhibiteur de xanthine oxydase
TW202313568A (zh) * 2021-05-21 2023-04-01 大陸商江蘇恒瑞醫藥股份有限公司 Btk抑制劑中間體的製備方法
TW202342456A (zh) * 2022-04-27 2023-11-01 大陸商江蘇新元素醫藥科技有限公司 可用於降尿酸的化合物
CN116283946B (zh) * 2023-03-27 2024-05-07 武汉工程大学 5-(n-取代吲哚-5-基)异噁唑-3-甲酸衍生物及其合成方法和应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003055882A1 (fr) * 2001-12-24 2003-07-10 Merck Patent Gmbh Pyrrolopyrimidines en tant d'agents d'inhibition de phosphodiesterase-vii
US20040034009A1 (en) * 2002-08-13 2004-02-19 Roark William Howard 1,6-Fused uracil derivatives as matrix metalloproteinase inhibitors
WO2008126898A1 (fr) * 2007-04-11 2008-10-23 Kissei Pharmaceutical Co., Ltd. Dérivé d'(aza)indole et ses usages médicaux

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003055882A1 (fr) * 2001-12-24 2003-07-10 Merck Patent Gmbh Pyrrolopyrimidines en tant d'agents d'inhibition de phosphodiesterase-vii
US20040034009A1 (en) * 2002-08-13 2004-02-19 Roark William Howard 1,6-Fused uracil derivatives as matrix metalloproteinase inhibitors
WO2008126898A1 (fr) * 2007-04-11 2008-10-23 Kissei Pharmaceutical Co., Ltd. Dérivé d'(aza)indole et ses usages médicaux

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
RACHID BENHIDA ET AL., TETRAHEDRON LETTERS, vol. 40, 1999, pages 5701 - 5703 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9156845B2 (en) 2012-06-29 2015-10-13 Pfizer Inc. 4-(substituted amino)-7H-pyrrolo[2,3-d] pyrimidines as LRRK2 inhibitors

Also Published As

Publication number Publication date
WO2010093191A2 (fr) 2010-08-19
KR20100092909A (ko) 2010-08-23

Similar Documents

Publication Publication Date Title
WO2011043568A3 (fr) Nouveaux composés efficaces comme inhibiteurs de la xanthine oxydase, leur procédé de préparation et composition pharmaceutique les contenant
WO2010093191A3 (fr) Nouveaux composés efficaces en tant qu'inhibiteurs de xanthine oxydase, leur procédé de préparation et composition pharmaceutique les contenant
WO2008005877A3 (fr) Inhibiteurs de c-kit et leurs utilisations
MY150596A (en) Hsp90 inhibitors
EP2457908B8 (fr) Procédé pour la préparation de composés utiles en tant qu'inhibiteurs de SGLT
WO2010008847A3 (fr) Inhibiteurs de pi3k/m tor
WO2011033265A8 (fr) Composés pharmaceutiques
WO2009108383A3 (fr) Dérivés de xanthine substitués
WO2008033836A3 (fr) Processus et intermédiaires destinés à préparer des inhibiteurs d'intégrase
MY165087A (en) Neprilysin inhibitors
MY170935A (en) Neprilysin inhibitors
MX354476B (es) Inhibidores de neprilisina.
WO2009156179A8 (fr) Her3 en tant que déterminant pour le pronostic du mélanome
AP2013006690A0 (en) Process for preparation of HIV protease inhibitors
WO2008075205A3 (fr) Procédé amélioré de préparation de la voriconazole
WO2010098583A2 (fr) Nouveau procédé de préparation de composés de statine ou des sels de ceux-ci, et composés intermédiaires utilisés dans ce procédé
WO2010015656A3 (fr) Nouveaux alcoxypyrazoles
WO2010006904A3 (fr) Nouvelles formes cristallines du rabéprazole sodique
WO2010107809A3 (fr) Procédés de préparation de composés inhibiteurs de la dpp-iv
WO2008089005A3 (fr) Inhibiteurs de rénine
WO2011083495A3 (fr) Procédé de préparation de dérivés protégés par un dihydroxy et nouveaux composés intermédiaires
WO2009007747A3 (fr) Nouveaux composés
WO2010023197A3 (fr) Nouveaux dérivés de piperidine-4-acetamide et utilisation de ceux-ci en tant qu'inhibiteurs du recaptage des neurotransmetteurs monoamines
EP2291077A4 (fr) Processus de préparation de composés inhibiteurs de rho-kinase
WO2010111634A3 (fr) Inhibiteurs de la rénine

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10741408

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORMS 1205A DATED 03.11.2011 AND 06.12.2011)

122 Ep: pct application non-entry in european phase

Ref document number: 10741408

Country of ref document: EP

Kind code of ref document: A2